Pancreatic adenocarcinoma presents as a spectrum of a highly aggressive disease in patients. The basis of this disease heterogeneity has proved difficult to resolve due to poor tumor cellularity and extensive genomic instability. To address this, a dataset of whole genomes and transcriptomes was generated from purified epithelium of primary and metastatic tumors. Transcriptome analysis demonstrated that molecular subtypes are a product of a gene expression continuum driven by a mixture of intratumoral subpopulations, which was confirmed by single-cell analysis. Integrated whole-genome analysis uncovered that molecular subtypes are linked to specific copy number aberrations in genes such as mutant KRAS and GATA6. By mapping tumor genetic his...
Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by a 5-year survival rate of 4%...
Despite the genomic characterization of pancreatic cancer (PC), marked advances in the developm...
Despite the genomic characterization of pancreatic cancer (PC), marked advances in the development o...
Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32 recurrently mutat...
Pancreatic cancer remains one of the most lethal of malignancies and a major health burden. We perfo...
Pancreatic cancer, a highly aggressive tumour type with uniformly poor prognosis, exemplifies the cl...
Pancreatic cancer is an aggressive malignancy with a five-year mortality of 97-98%, usually due to w...
Despite the genomic characterization of pancreatic cancer (PC), marked advances in the development o...
DNA copy number alterations are believed to play a major role in the development and progression of ...
With less than a 5% survival rate pancreatic adenocarcinoma (PDAC) is almost uniformly lethal. In or...
Pancreatic ductal adenocarcinoma is a highly lethal malignancy, which has now become the seventh mos...
Background: A deeper knowledge of the pancreatic cancer (PDAC) biology is needed to improve the prog...
Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by a 5-year survival rate of 4%...
Despite the genomic characterization of pancreatic cancer (PC), marked advances in the developm...
Despite the genomic characterization of pancreatic cancer (PC), marked advances in the development o...
Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32 recurrently mutat...
Pancreatic cancer remains one of the most lethal of malignancies and a major health burden. We perfo...
Pancreatic cancer, a highly aggressive tumour type with uniformly poor prognosis, exemplifies the cl...
Pancreatic cancer is an aggressive malignancy with a five-year mortality of 97-98%, usually due to w...
Despite the genomic characterization of pancreatic cancer (PC), marked advances in the development o...
DNA copy number alterations are believed to play a major role in the development and progression of ...
With less than a 5% survival rate pancreatic adenocarcinoma (PDAC) is almost uniformly lethal. In or...
Pancreatic ductal adenocarcinoma is a highly lethal malignancy, which has now become the seventh mos...
Background: A deeper knowledge of the pancreatic cancer (PDAC) biology is needed to improve the prog...
Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by a 5-year survival rate of 4%...
Despite the genomic characterization of pancreatic cancer (PC), marked advances in the developm...
Despite the genomic characterization of pancreatic cancer (PC), marked advances in the development o...